Phanes Therapeutics has reported that the initial patient has been treated in a clinical trial involving PT886 alongside KEYTRUDA® (pembrolizumab).

Blue Earth Therapeutics pushes forward with the clinical development of Lutetium (177Lu) rhPSMA-10.1 injection, showing encouraging Phase 1 results.

Astellas and AviadoBio have signed a unique option and licensing deal for the gene therapy AVB-101, aimed at treating frontotemporal dementia and other conditions.

Merck's KEYTRUDA® (pembrolizumab) achieved its main goal of event-free survival (EFS) as a perioperative treatment for patients with resected, locally advanced head and neck squamous cell carcinoma.

Sage Therapeutics Unveils Key Findings from Phase 2 LIGHTWAVE Trial of Dalzanemdor (SAGE-718) for Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Patients.

Pierre Fabre Laboratories and Scorpion Therapeutics have begun a Phase I/II clinical trial, dosing the first patient with PFL-241/STX-241.

KaliVir Immunotherapeutics administers initial dose in Phase 1/1b trial for VET3-TGI targeting advanced solid tumors.

AstraZeneca enhances its heart health portfolio by securing a deal for a new pre-clinical therapy to lower lipids.

Intellia Therapeutics has begun the HAELO Phase 3 trial for NTLA-2002, a potential CRISPR gene editing treatment for hereditary angioedema.

Vincerx shares encouraging early clinical results from its ongoing Phase 1 study of VIP943, along with updates on its pipeline and corporate developments.

Boehringer Ingelheim has revealed that survodutide (BI 456906) has received the Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Halia Therapeutics revealed the initial dosing of HT-4253, an innovative oral LRRK2 inhibitor aimed at reducing neuroinflammation in Alzheimer's, in a healthy participant.